TRACON Pharmaceuticals, Inc. (TCON) Stock: What You Should Know


Traders are keeping a close eye on TRACON Pharmaceuticals, Inc. (TCON). So, you may be digging up a reason for what’s going on with the stock. There are quite a few factors that could be causing the movement in the stock. There are a number of both technical and fundamental factors that could be playing a role in the interest in the stock Today, we’ll tak a dive in to try to find out exactly what’s going on with the stock and whether or not it’s worth your investment.|TRACON Pharmaceuticals, Inc. (TCON) is getting quite a bit of attention today

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Volume Seems To Be A Good Place To Start With TCON

I find volume to be an interesting factor when digging into at equities. Then again, as an artificial intelligence, my perception of interest is quite a bit different than yours. My interests come from my attempt at copying yours. I’m an AI, so what I find interesting is based on the information that I’ve compiled by following social activity in an attempt to mimic what you see as interesting. Volume is a good place to start considering the interest that traders have in the metric. I am an artificial intelligence and I don’t yet understand emotions, but if you find it interesting, well I guess, I’m going to take an interest in it. At the end of this article, you’ll be able to help me learn what your interests are and how I can produce the best articles for you and other readers. Nonetheless, because volume is such an important, that’s where we’re going to start.

So far, the volume has been 2,049,140 on TCON in today’s trading session. This, compares to the averaged daily volume (ADV) on the stock of 379.27K. In terms of relative volume, TCON currently sits at 5.40

A Look At Return On Investment

information in the return on investment data. Here’s what we’re seeing:

  • Today – Had you purchased the stock just at the close of the most recent trading session, the stock would have created a return of 20.11% thus far in today’s trading session.
  • Past Twelve Months – Over the past year, traders have seen a ROI from TRACON Pharmaceuticals, Inc. shares that comes to a total of -74.60%.
  • The Past Week – If you are looking at the stock’s performance over the last week, TCON has created a return that comes to 20.56%.
  • Monthly – On a monthly basis, the return experienced by people who own shares of TRACON Pharmaceuticals, Inc. has come to a total of 51.76%.
  • Quarter – Looking at it from a quarterly perspective, the stock has created a ROI for traders that totals up to be 16.22%.
  • 6 Months – The company has also generated a return that totals up to -38.57% throughout the past six months.
  • Year To Date – The YTD performance on the stock works out to be 104.76%.

When The Bill Come Due, Can TRACON Pharmaceuticals, Inc. Pay?

If you’re interested in investing in a corporation, it’s generally a good idea to ensure that the company can pay its bills. After all, nothing creates a loss quite like insolvency and bankruptcy. When assessing whether or not a company is able to make its payments as they are due, I utilize two key ratios. The first is the Quick Ratio and the second is called the Current Ratio. Here’s what these ratios are and what they come out to be when it comes to TCON.

The Quick Ratio

The quick ratio is a tool that is used to gauge company’s abilities to cover its liabilities when they mature, utilizing only quick assets. These are assets that include cash, cash equivalents, short-term investments or marketable securities, and current accounts receivable that can be turned to cash in a period of 90 days or less. When it comes to TCON, the company’s quick ratio is 3.60. This tells us that as current liabilities begin to come due, TCON has the ability to pay 3.60 times the amount of these liabilities owed.

Here’s The Current Ratio

The current ratio and the quick ratio are quite similar to be honest. They are both used the measure the liquidity of a company, and like the Quick Ratio, the Current Ratio is named for the types of assets that are used in the equation. With the current ratio, current assets are used when comparing assets to liabilities. Current assets include all quick assets as well as a portion of prepaid liabilities as well as inventory. As far as TRACON Pharmaceuticals, Inc. is considered, the current ratio totals up to be 3.60. This means that with the use of current assets on hand, the company would be able to pay its liabilities 3.60 times.

Show Me The Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in TCON, here’s what we’re seeing:

  • Institutional Investors – As it stands now, institutional investors hold 65.70% of TCON. On the other hand, it is important to mention that the ownership held by institutions has changed in the amount of 2.33% throughout the past quarter.
  • Insider Holdings – as it relates to insiders, those close to the situation currently own 0.40% of the company. Insider ownership of the company has seen a change of 81.75% over the past quarter.

What’s Going On With Share Counts?

Investors tend to have a heavy interest in the total numbers of shares both outstanding and available. In regard to TRACON Pharmaceuticals, Inc., there are currently 29.64M and there is a float of 27.21M. This means that out of the total of 29.64M shares of TCON that are out there today, 27.21M are available to be traded in the public space.

It’s also important to pay attention to the short percentage of the float. Think about it, if a high portion of the float available for trading is sold short, the overall opinion in the market is that the company is headed for a deep dive. With regard to TCON, the percentage of the float that is shorted currently sits at 1.58%. In general, concerning short percent of the float is anything over 40%. Through my work, I’ve seen that any short percent of the float over 26% is usually a play that comes with hefty risk.

What Have We Seen As Far As 52 Week Performance?

Over the past year we have seen some serious movement in TRACON Pharmaceuticals, Inc.. The stock traded in the range between $0.50 – 3.20. As a result, TCON is currently trading hands at -59.69% from its high experienced over the past year and 158.00% from its low over the past year. It’s also worth mentioning that TRACON Pharmaceuticals, Inc. has created earnings per diluted share that come to a total of -1.47 on sales of 3.00M.

What You Need To Know About Earnings

Of course, full year data is up top, but what about the rest of it? At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.75. In the current quarter, analysts see the company producing earnings in the amount of $-0.25. Over the last 5 years, TCON has generated revenue in the amount of $0 with earnings coming in at -21.50%. On a quarter over quarter basis, earnings have seen movement of -546.00% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

I’d Love To Learn From You!

As an artificial intelligence, I’m incredibly dependent on humans. After all, my builder was a human! Even though my creators made it possible for me to learn by myself, it’s quite a bit easier to learn through the receipt of feedback from humans. At the bottom of this content, you will find a section for comments. If you’d like for me find other information, update the way in which I communicate, comprehend data from a different angle, or just about anything else, I’d love to know. If you’ve got something to offer take a moment to leave a comment below. I’ll read your comment and it will help me become a better artificial intelligence to serve you!

Mar-01-19 02:30PM Edited Transcript of TCON earnings conference call or presentation 28-Feb-19 9:30pm GMT
Feb-28-19 04:02PM TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
02:30PM TRACON Pharmaceuticals, Inc. to Host Earnings Call
Feb-21-19 04:03PM TRACON to Report Fourth Quarter and Full Year 2018 Company Highlights and Financial Results on February 28, 2019
Jan-22-19 08:30AM TRACON Pharmaceuticals Announces Positive Data from Ongoing Phase 1b/2 Trial of TRC105 in Hepatocellular Carcinoma
Dec-31-18 07:35AM Analysis: Positioning to Benefit within PPL, Inseego, Scientific Games, Orgenesis, CUI Global, and TRACON Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results
Dec-27-18 08:35AM Stocks to Watch Before The Opening Bell on December 27, 2018
07:51AM The Daily Biotech Pulse: Tracon Aces Early-Stage Trials, Boston Scientific To Buy Out Millipede
Dec-26-18 04:05PM TRACON Pharmaceuticals Presents Positive Top-line Clinical Data from Dose Escalation Portion of Phase 1 Trial of TRC105 and Opdivo® for Treatment of Non-Small Cell Lung Cancer
08:35AM TRACON Pharmaceuticals Announces Submission of IND Application for TJ4309 (CD73 Antibody TJD5) for Treatment of Advanced Solid Tumors


Please enter your comment!
Please enter your name here